SCHEMBL24953866

SCHEMBL24953866

C[C@H](O)CN(C)C(=O)Nc1ncc(Cc2c(F)cccc2F)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ ABL1 P00519 3/20 0.42
▸ MEN1 O00255 7/20 0.41
▸ KMT2A Q03164 7/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LMNA P02545 6/20 0.40
▸ NPC1 O15118 5/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ NFKB1 P19838 2/20 0.39
▸ NFKB2 Q00653 2/20 0.39
▸ RELA Q04206 2/20 0.39
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24953879 0.89 POLB (0.50) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24952928 0.88 ABL1 (0.56) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24953645 0.88 ABL1 (0.56) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24953757 0.88 ABL1 (0.56) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24953789 0.85 MAPT (0.53) MAPTABL1MEN1KMT2AL3MBTL1
SCHEMBL24953812 0.85 MAPT (0.53) MAPTABL1MEN1KMT2AL3MBTL1
SCHEMBL24952951 0.84 MEN1 (0.57) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24954084 0.83 SCD (0.50) MAPTABL1MEN1KMT2AL3MBTL1
SCHEMBL24954089 0.82 MEN1 (0.43) MAPTPOLBABL1MEN1KMT2A
SCHEMBL24953677 0.82 GPER1 (0.50) MAPTPOLBABL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230029266-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders DERMIRA, INC. 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230029266-A1 MrgprX2 Antagonists for the Treatment of Inflammatory Disorders MRGPRX2, MRGPRX1, MRGPRX4 MAPT 3161/4885POLB 4455/4885ABL1 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback